Quarterly insight from our fixed income teams to help clients navigate the markets and opportunities ahead.
As growth companies race to capture network effects and value companies cling to legacy economics, investors may find opportunity somewhere in between.
After hitting roadblocks last week, the effort to lower drug prices in the U.S. is changing course, with implications for investors.
Dividend growth was better than expected in the first half of 2019. Can the pattern continue for the rest of the year?
Companies across all industries are working to transition to a digital economy – some with more success than others.
Nick Cherney explains how thematic investing allows investors to tap into opportunities presented by broad macroeconomic trends, such as the growing organics market.
Andy Acker discusses how biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows.
With the current cycle particularly long in the tooth, Portfolio Managers Ted Thome and Alec Perkins discuss why investors should consider allocating to defensive value.
Watching for the mega trends that have the potential to spark disruption and create opportunities.
Co-Head of Equities George Maris suggests opportunities can be found in both growth and value stocks and urges investors to focus on fundamentals.
Read the latest insights from our research team and learn how they are navigating the opportunities and risks within each sector.
Why investors should balance the massive earnings potential of SaaS companies and their sometimes lofty valuations.
Focusing on secular growth drivers as the technology and health care sectors experience rapid change – and bouts of volatility.